首頁 > 市場調查報告書 > 製藥

神經疾病

中樞神經系統治療市場規模、佔有率和成長分析（按藥物類型、疾病類型、給藥途徑、分銷管道和地區分類）－產業預測（2026-2033年）

市場調查報告書

商品編碼

1899348

中樞神經系統治療市場規模、佔有率和成長分析（按藥物類型、疾病類型、給藥途徑、分銷管道和地區分類）－產業預測（2026-2033年）

Central Nervous System Treatment Market Size, Share, and Growth Analysis, By Drug Type (Anesthetics, Anticonvulsants), By Disease Type, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月16日 | 出版商:

SkyQuest | 英文 260 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球中樞神經系統治療市場規模預計在 2024 年達到 1,449.6 億美元，從 2025 年的 1,540.9 億美元成長到 2033 年的 2,512.2 億美元，在預測期（2026-2033 年）內複合年成長率為 6.3%。

全球慢性疾病和中樞神經系統（CNS）疾病的日益普遍凸顯了有效治療方案的迫切需求。神經外科醫生、神經內科醫生和物理治療師等多學科專家的協作對於提供全面護理至關重要。神經科學的持續進步正在推動創新治療方法的研發，包括新的外科手術、基因療法和先進的神經影像技術。由於診斷能力的提升和中樞神經系統疾病發病率的上升，全球中樞神經系統治療市場預計將持續成長。專利到期後，學名藥的普及將加劇市場競爭，尤其有利於中低收入國家。監管支援和重點臨床試驗正在推動新型治療方法的引入，而近期的研發工作也為中樞神經系統治療的先進藥物遞送系統鋪平了道路。

全球中樞神經系統治療市場成長要素

全球中樞神經系統治療市場的主要驅動力是多發性硬化症、阿茲海默症和帕金森氏症等神經系統疾病盛行率的不斷上升。病例數的激增在全球日益顯著，對市場擴張產生了重大影響。此外，人口老化國家阿茲海默症病例也相應增加。目前，數百萬人受此疾病影響，預計未來這數字將持續大幅成長。隨著這些挑戰日益嚴峻，對有效治療方法和介入的需求預計將會增加，從而進一步推動市場成長。

限制全球中樞神經系統治療市場發展的因素

與其它領域相比，中樞神經系統治療市場面臨許多限制因素，其中治療研發所需的巨額投資尤為突出。針對中樞神經系統的治療方法複雜且精密，需要高度精準的操作，導致能夠應對這些挑戰的合格醫療專業人員短缺。此外，影響大腦功能或行為的治療藥物核准流程歷時漫長，往往需要數年時間，阻礙了這個重要醫學領域的及時發展和藥物普及。

全球中樞神經系統治療市場趨勢

全球中樞神經系統（CNS）治療市場正經歷強勁成長，主要得益於神經系統疾病的增加、人口老化以及藥物研發的進步。公共和私營部門的快速投資正在推動創新治療方法的研發，包括生物製藥和個人化醫療。此外，數位健康技術和人工智慧在治療通訊協定中的日益融合正在重塑患者照護路徑，從而帶來更有效、更個人化的治療選擇。公眾意識的提高和診斷能力的提升進一步推動了市場需求，中樞神經系統治療領域正逐漸成為醫療保健領域充滿活力和核心地位的領域。

神經退化性疾病
- 阿茲海默症
- 帕金森氏症
- 亨丁頓舞蹈症
- 多發性硬化症
- 肌萎縮側索硬化症（ALS）
- 其他
精神疾病
- 憂鬱症
- 思覺失調症
- 躁鬱症
- 癲癇
- 焦慮症
- 其他
神經血管疾病
- 中風
- 腦動脈瘤
- 血管性失智症
- 其他
感染疾病
- 腦膜炎
- 腦炎
- 其他
創傷性中樞神經系統疾病
- 創傷性腦損傷
- 脊髓損傷
- 其他
中樞神經系統癌症
其他

全球中樞神經系統治療藥物市場規模（按給藥途徑和複合年成長率分類）（2026-2033 年）

口服
注射
經皮
鼻腔
其他

全球中樞神經系統治療藥物市場規模（按分銷管道分類）及複合年成長率（2026-2033 年）

醫院藥房
零售藥房
網路藥房
藥局
其他

全球中樞神經系統治療藥物市場規模及複合年成長率（2026-2033）

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Johnson & Johnson
Bristol Myers Squibb
Otsuka Pharmaceutical Co., Ltd.
Eli Lilly
Biogen
Genentech/Eisai
Roche
Neurocrine Biosciences
Novartis
Pfizer
Sanofi
Merck & Co.
GSK
AstraZeneca
Teva Pharmaceuticals
H. Lundbeck
Acorda Therapeutics
Alzheon
Delix Therapeutics
Cerevel Therapeutics

結論與建議

簡介目錄

Product Code: SQMIG35B2179

Global Central Nervous System Treatment Market size was valued at USD 144.96 Billion in 2024 and is poised to grow from USD 154.09 Billion in 2025 to USD 251.22 Billion by 2033, growing at a CAGR of 6.3% during the forecast period (2026-2033).

The increasing prevalence of chronic and central nervous system (CNS) disorders globally underscores the need for effective treatment solutions. A multidisciplinary approach involving specialists such as neurosurgeons, neurologists, and physical therapists is essential for comprehensive care. Ongoing advancements in neuroscience are fueling the development of innovative treatment options, including new surgical techniques, gene therapies, and enhanced neuroimaging technologies. The global market for CNS treatments is anticipated to grow due to rising diagnostic capabilities and the increasing incidence of CNS disorders. The shift towards generic medications, facilitated by patent expirations, particularly benefits low- and middle-income countries, enhancing market competition. Regulatory support and focused clinical trials foster the introduction of novel therapies, while recent R&D efforts have paved the way for advanced drug delivery systems in CNS treatment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Central Nervous System Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Central Nervous System Treatment Market Segments Analysis

Global Central Nervous System Treatment Market is segmented by Drug Type, Disease Type, Route of Administration, Distribution Channel and region. Based on Drug Type, the market is segmented into Anesthetics, Anticonvulsants, Antidepressants, Antiemetics, CNS Stimulants, Anti-Parkinson's Drugs, Anti-Alzheimer's Drugs, Pain Relievers and Others. Based on Disease Type, the market is segmented into Neurodegenerative Diseases, Mental Health Disorders, Neurovascular Diseases, Infectious Diseases, Trauma-related CNS Disorders, CNS Cancer and Others. Based on Route of Administration, the market is segmented into Oral, Injectable, Transdermal, Intranasal and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Central Nervous System Treatment Market

The global Central Nervous System Treatment market is being strongly driven by the escalating prevalence of neurological disorders, such as multiple sclerosis, Alzheimer's disease, and Parkinson's disease. This surge in cases is becoming increasingly evident around the world, significantly influencing market expansion. Moreover, nations with growing elderly populations are witnessing a corresponding rise in Alzheimer's disease cases. Currently, millions are affected by this condition, and projections indicate that this number will continue to climb dramatically in the foreseeable future. As these challenges become more pronounced, the demand for effective treatments and interventions is anticipated to escalate, further propelling market growth.

Restraints in the Global Central Nervous System Treatment Market

The Global Central Nervous System Treatment market faces several constraints, largely due to the substantial investments required for therapeutic research and development compared to other areas. The complexity of therapies targeting the central nervous system necessitates a high level of precision, which in turn leads to a shortage of qualified medical professionals equipped to handle these challenges. Additionally, the process of obtaining drug approval for treatments that influence brain function and behavior is notoriously protracted, often spanning several years, thereby hindering timely advancements and accessibility in this crucial field of medicine.

Market Trends of the Global Central Nervous System Treatment Market

The Global Central Nervous System (CNS) Treatment market is experiencing robust growth driven by an increase in neurological disorders, rising aging populations, and advancements in pharmaceutical research. A surge in investments from both public and private sectors is enhancing the development of innovative therapies, including biologics and personalized medicine. Additionally, the integration of digital health technologies and artificial intelligence in treatment protocols is reshaping patient care pathways, resulting in more effective and tailored treatment options. Growing awareness and improved diagnostic capabilities are further propelling demand, positioning the CNS treatment sector as a dynamic and pivotal area within the healthcare landscape.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index, 2025
PESTEL Analysis
Technology Analysis
Case Studies
Patent Analysis
Value Chain Analysis
Trade Analysis
Pipeline Analysis
Clinical Trials
Raw Material Analysis
Startup Analysis
Pricing Analysis
Regulatory Analysis

Global Central Nervous System Treatment Market Size by Drug Type & CAGR (2026-2033)

Market Overview
Anesthetics
Anticonvulsants
Antidepressants
Antiemetics
CNS Stimulants
Anti-Parkinson's Drugs
Anti-Alzheimer's Drugs
Pain Relievers
Others

Global Central Nervous System Treatment Market Size by Disease Type & CAGR (2026-2033)

Market Overview
Neurodegenerative Diseases
- Alzheimer's Disease
- Parkinson's Disease
- Huntington's Disease
- Multiple Sclerosis
- Amyotrophic Lateral Sclerosis (ALS)
- Others
Mental Health Disorders
- Depression
- Schizophrenia
- Bipolar Disorder
- Epilepsy
- Anxiety Disorders
- Others
Neurovascular Diseases
- Stroke
- Cerebral Aneurysm
- Vascular Dementia
- Others
Infectious Diseases
- Meningitis
- Encephalitis
- Others
Trauma-related CNS Disorders
- Traumatic Brain Injury
- Spinal Cord Injury
- Others
CNS Cancer
Others

Global Central Nervous System Treatment Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Injectable
Transdermal
Intranasal
Others

Global Central Nervous System Treatment Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores
Others

Global Central Nervous System Treatment Market Size & CAGR (2026-2033)

North America (Drug Type, Disease Type, Route of Administration, Distribution Channel)
- US
- Canada
Europe (Drug Type, Disease Type, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Type, Disease Type, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Type, Disease Type, Route of Administration, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Type, Disease Type, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genentech/Eisai
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neurocrine Biosciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GSK
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
H. Lundbeck
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acorda Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alzheon
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Delix Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cerevel Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments